Significant Enhancements Announced for Pathway, VeraSci’s Proprietary eCOA Platform

Significant Enhancements Announced for Pathway,

VeraSci’s Proprietary eCOA Platform

Integrating Clinical, Cognitive and Functional Assessments onto one device.

 

Durham, NC—December 6, 2018—VeraSci, a global clinical technology and research services company, announces multiple significant enhancements to Pathway, their proprietary eCOA platform. Pathway, which reinvented how raters, sponsors and site administrators conduct assessments and scales for clinical trials, now offers enhanced data collection and administration, and access to a larger number and type of scales and assessments.

The Pathway team worked with raters, scale-developers, and sponsors to ensure that all Pathway users would derive optimal functionality while accommodating the needs of each study and site. The improved flexibility of Pathway allows for the use of a single device for multiple assessments and multiple protocols, permits high enrolling sites to use different devices for parallel assessment of multiple patients, and easily integrates all of the data. VeraSci’s proprietary assessments, BAC and VRFCAT, and licensed gold standard endpoints and safety measures for multiple therapeutic areas such as the EDSS and C-SSRS, are now accessible through a single Pathway-enabled device. In addition, raters can administer assessments on Pathway and obtain consent from test subjects on the same device.

Available in multiple languages, Pathway is able to accommodate a sponsor’s specific needs for an integrated experience in a variety of countries, with negligible failure rates or device issues. VeraSci’s multi-lingual tech support teams in Europe, Asia, and the United States provide support in sites’ local languages, and VeraSci’s Global Language Solutions team provides scientifically valid translations and cultural adaptations of required assessments.

The feedback from users has been extraordinary. Dave Walling, Ph.D. of CNS Network LLC, explains, “Pathway simplifies the process for raters at the site level by integrating the assessments into one system. Rating on a tablet can often be a frustrating experience as there are multiple log-ins, connection problems, and technological mishaps…Pathway helps to combat those issues and makes the process easier for staff, subjects and ultimately, sponsors”.

If you are interested in learning more about Pathway, an FDA 21 CFR Part 11 Compliant eCOA platform, visit our website; https://verascience.com/what-we-do/our-solutions/pathway/

About VeraSci

Founded in 2004, VeraSci has a worldwide presence in clinical trial development, clinical and cognitive assessment and language services. VeraSci brings deep expertise, strategic innovation and unwavering commitment to every project, allowing each client to deliver data supporting innovative therapies.

###

VeraSci is a registered trademark of NCT Holdings in the United States and/or other countries.

I'm interested in Pathway

  • By sending us your information, you are agreeing to allow VeraSci to retain certain personal information provided by you in order to contact you in the future. If you have any questions about how we handle your data, please refer to our Privacy Policy located at https://www.verascience com/privacy-policy/

 

 

 

 

NeuroCog Trials is now VeraSci

Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery. They are also merging NeuroCog Trials with NCT Linguistics, formerly a division of NeuroCog Trials, under the VeraSci brand. The name change was driven by the company’s expansion into new therapeutic areas, their larger global and language footprints, and the broadening of the scope of services and technology they provide as partners to industry, academic and government programs. To support this vital new company, they have launched www.VeraScience.com, a dynamic website that reflects their new branding while showcasing the full depth and breadth of their expanded offerings and progressive movement into new areas of expertise.

Caren Gadigian, President at VeraSci, stated, “Over the 14 years since our inception, we have expanded our areas of expertise and innovation to include a variety of clinical and regulatory endpoints over a range of human disorders and diseases. We have also developed a multitude of technological advances that are changing the way human assessment is conducted in clinical research across the world.”

The Evolution from NeuroCog Trials to VeraSci

When first incorporated in 2004, NeuroCog Trials focused primarily on the development and support of cognitive endpoints for clinical trials. In response to frequent sponsor requests, over time they have amplified their expertise to include areas such as mood disorders, movement disorders, psychosis, oncology and rare and orphan diseases. Due to their increased participation in trials outside the US, their language service offerings have also grown. Today, they specialize in translation, localization, interpretation and training in over 150 different languages and provide language services worldwide.

Throughout this growth they have continually kept their finger on the pulse of technological advancements in and around the pharmaceutical industry. Through the VeraSci Innovation Lab, their scientists and technicians fuse next-generation technology with data collection into many of their proprietary eCOA tools, all of which are easily configured to best meet the needs of any study.

“Given these exciting developments, and our new collaborations with partners in technology and medicine” stated Dr. Richard Keefe, VeraSci CEO, “we wanted our name to reflect the broad range of our new activities as well as our ongoing commitment to our foundational principles of scientific integrity and true signal identification in the noisy real-world environment of clinical trials research.”

An Improved Digital Experience

Customer feedback was a catalyst for the design and development of VeraScience.com, which informs visitors of their robust proprietary product offerings and expanded expertise in multiple therapeutic areas and language services. The mobile-friendly site offers easy navigation to four main areas, presented in a clean, uncluttered environment that was created with the user-experience front of mind. Visitors will also be able to access a calendar of events and library of resources that highlight VeraSci’s ongoing involvement in the eCOA and clinical trial development industry, as well as a link to their Careers page.

About VeraSci

Founded in 2004, VeraSci has a worldwide presence in clinical trial support, clinical and cognitive assessment, and language services. The company offers a robust platform of products and services that positions them as an ideal research partner anywhere on the globe. VeraSci’s areas of expertise have continually expanded and grown since inception, allowing them to offer validated full service solutions to clients. VeraSci brings deep expertise, strategic innovation and unwavering commitment to each and every client and project, allowing them to deliver data supporting innovative therapies to reduce suffering.

LEADING ALZHEIMER’S DISEASE SCIENTIST JOINS NEUROCOG TRIALS

DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials (NCT) providing thought leadership in Neurodegenerative Disorders. With more than 25 years of research dedicated to this therapeutic area, Dr. Welsh-Bohmer lends the highest level of scientific expertise to the continued development of effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring later in life.

(more…)

NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease

Innovative technology answers the call for improved functional capacity measurements in cognitive disorders

Durham, North Carolina, October 30, 2017 NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company, today announced it received a 2017 Fast Track grant from the National Institute of Health (NIH) to study the validation of a performance-based measure of functioning in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease (AD) using NCT’s proprietary technology, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The VRFCAT is a state-of-the-art solution developed to improve clinical trials by detecting functionally meaningful improvements in patient’s everyday lives.

(more…)

FORMER DIRECTOR GENERAL OF THE ITALIAN MEDICINES AGENCY (AIFA) DR. LUCA PANI JOINS NEUROCOG TRIALS

Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider

DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani, as Executive Director of Global Medical Innovation.  Dr. Pani will guide the company’s development of innovative solutions for clinical trials methodologies and health outcomes.

During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models are now being used in many other countries.  As a European Regulator, Dr. Pani has not only been a leading figure for the Approval and Scientific Advice for Central Nervous System products, but also has served as Chair of the Telematics Committee.  While in AIFA Dr. Pani worked on the approvals of pharmaceutical products in a broad range of all therapeutic areas including oncology, immunology, cardiovascular and CNS disorders.

“I am privileged to have someone with Dr. Pani’s extraordinary background and expertise in regulatory, academic and industry science come to NeuroCog Trials as we expand the breadth of solutions we offer for clinical trial methodologies. Dr. Pani will have an immediate impact and provide deep insight and perspective into our development of innovative strategies for transforming the current landscape,” said Co-Founder and CEO, Dr. Richard Keefe.

NCT offers clients global and regional study design strategies, protocol advisory and measure selection services as well as technology solutions that maximize opportunities for success by adhering to the highest scientific principles and regulatory standards across all clinical phases.  Dr. Pani’s expertise innovating health economics and outcomes research will become a central element of NCT’s services.

Dr. Pani is the author or co-author of hundreds of publications and is an internationally recognized speaker at scientific meetings and conferences.  He is also professor of Psychiatry at the University of Miami.  In addition, his most recent book, Sustainable Innovation: Medicines and the Challenges for the Future of our National Health Service has been published to acclaim.  He has served on the editorial boards of many prestigious scientific journals including Clinical Neuropsychiatry, Italian Journal of Psychiatry and Psychotherapy, and the Italian Edition of the American Journal of Psychiatry.

He received his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois and Georgetown University.

About NeuroCog Trials

NeuroCog Trials (NCT) is a global cognition and clinical assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications.  NCT has provided consulting, site screening, rater training and certification, translation, and data services for more than 100 clinical trials in over 25 countries.  Founded in 2005, NCT is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.

NCT Linguistics Sponsors Triangle Biotech Tuesday – Press Release

DURHAM, NORTH CAROLINA, May 19, 2017

NCT Linguistics, a leading global provider of translation, interpretation, and training services, was honored to sponsor Triangle Biotech Tuesday in Research Triangle Park on Tuesday, May 9, 2017. Triangle Biotech Tuesday is a not-for-profit event to connect scientific professionals, facilitate collaborations, and foster communications throughout the Research Triangle.

Triangle Biotech Tuesday’s local platform joined professionals across industries representing scientific, clinical research, pharmaceutical, and academic arenas. Food, drink, and informative conversation created a community of future-focused colleagues. This was a premier event to increase knowledge and resources within the Triangle area. NCT Linguistics’ personnel were on hand to answer questions about their growing language services company and to participate in local initiatives that shape the Triangle.

About NCT Linguistics
NCT Linguistics, a division of NCT Holdings Inc. dba NeuroCog Trials, is a Woman Owned Small Business located in Durham, North Carolina, and provider of translation, localization, interpretation, and training services in over 150 languages supported by more than 1,500 certified linguists worldwide. Their services have covered the life science, pharmaceutical, medical, healthcare, manufacturing, government, engineering, and legal industries.

View or download the press release in a PDF